Lung Transplantation for Pleuroparenchymal Fibroelastosis

Lung Transplantation for Pleuroparenchymal Fibroelastosis : a French Multicentric Retrospective Study

This retrospective observational study will evaluate the outcomes of lung transplantation for a rare cause of interstitial lung disease called pleuroparenchymal fibroelastosis. Data will be collected from all transplantation center in France.

Study Overview

• Status: Recruiting
• Conditions: Fibroelastosis
• Intervention / Treatment: Procedure: Lung transplantation (single, lobar or bilateral lung transplantation)

• Study Type: Observational
• Enrollment (Anticipated): 30

Contacts and Locations

Study Locations

• France
  • Le Plessis-Robinson, France, 92350
    • Recruiting
    • Marie Lannelongue Hospital
    • Contact: : Elie FADEL : Elie FADEL, MD; Phone Number: 33 1 40 94 28 00; Email: e.fadel@ghpsj.fr
  • Lyon, France
    • Completed
    • Hôpital Louis Pradel
  • Paris, France
    • Recruiting
    • Bichat Claude Bernard Hospital, APHP
    • Contact: Pierre MORDANT, MD; Phone Number: + 33 1 40 25 64 40; Email: pierre.mordant@aphp.fr
  • Suresnes, France
    • Recruiting
    • Foch Hospital
    • Contact: Edouard SAGE Edouard SAGE, MD; Phone Number: : +33 1 46 25 28 26; Email: e.sage@hopital-foch.fr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Patients diagnosed with pleuroparenchymal fibroelastosis who underwent lung transplantation in France between 2005 and 2021.

Description

Inclusion Criteria:

• Lung transplantation (any type) for pleuroparenchymal fibroelastosis
• Histologically confirmed pleuroparenchymal fibroelastosis on the recipient lungs

Exclusion Criteria:

• All other interstitial lung disease than pleuroparenchymal fibroelastosis
• Pleuroparenchymal fibroelastosis who didn't underwent lung transplantation

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
lung transplantation; Lung transplantation performed for end-stage interstitial lung disease secondary to pleuroparenchymal fibroelastosis.	Procedure: Lung transplantation (single, lobar or bilateral lung transplantation); Lung transplantation were performed for end-stage interstitial lung disease secondary to pleuroparenchymal fibroelastosis

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Post-operative mortality	Any death after lung transplantation during the first 30 days or during the hospitalization following the lung transplantation (in-hospital mortality)	Any death up to 90 days after lung transplantation

Collaborators and Investigators

• Sponsor: Hospices Civils de Lyon

Study record dates

Study Major Dates

• Study Start (Actual): April 1, 2021
• Primary Completion (Actual): July 1, 2021
• Study Completion (Anticipated): November 1, 2021

Study Registration Dates

• First Submitted: August 30, 2021
• First Submitted That Met QC Criteria: September 6, 2021
• First Posted (Actual): September 14, 2021

Study Record Updates

• Last Update Posted (Actual): September 14, 2021
• Last Update Submitted That Met QC Criteria: September 6, 2021
• Last Verified: August 1, 2021

More Information

Terms related to this study

• Other Study ID Numbers: 420

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No